Background Although reoperative surgery in the central compartment (RCND) is indicated for bulky or progressive persistent/recurrent papillary thyroid carcinoma (PTC), its associated morbidity and disease outcomes remain unclear. We evaluated RCND outcomes by comparing them with those of patients who underwent primary central neck dissection (CND). Methods After matching for age, sex, tumor size, and initial tumor stage, the morbidity and outcomes of 50 consecutive patients who underwent RCND were compared with data from 75 patients who underwent primary therapeutic CND during the same period. Matching was performed blind to the morbidity and disease outcome of each patient. A stimulated thyroglobulin (sTg) \2 ng/ml was considered undetectable. Results Relative to primary CND, the incidence of extranodal extension (p = 0.010) and size of metastatic lymph nodes (p \ 0.001) were significantly greater in the RCND group. Postoperative hypoparathyroidism and vocal cord palsy rates were comparable in the groups. There were two esophageal injuries in the RCND group and none in the primary CND group. The secondary CND group achieved a significantly lower undetectable postablation sTg rate (12.0 vs. 52.0 %, p = 0.001) and worse 10-year disease-free survival (35.6 vs. 91.8 %, p = 0.001) and cancer-specific survival (82.0 vs. 98.5 %, p = 0.001) than the primary CND group. Conclusions Although RCND for persistent/recurrent PTC was performed with morbidity comparable to that seen with primary CND, it was associated with some serious complications. Short-and long-term disease control appeared moderate with approximately one-tenth of patients having an undetectable sTg level 6 months after ablation and one-third remaining clinically disease-free after 10 years.
Introduction
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma. Its age-adjusted incidence has doubled during the last two and a half decades [1, 2] . Despite its good prognosis with a 10-year cancer-specific survival (CSS) above 90 %, locoregional recurrence is relatively common [3] . Local recurrences are found in 5-20 % of patients with PTC, two-thirds of which are localized in the cervical lymph nodes [3] . With the availability of ultrasensitive thyroglobulin (Tg) assays and highresolution ultrasonography (USG), the identification of asymptomatic, small-volume metastatic cervical lymph nodes has become relatively common [4, 5] . Despite this, the benefit of surgically removing these small nodes remains unclear [4] . The revised American Thyroid Association recommends surgical removal only of clinically significant (i.e., [8 mm in diameter) metastatic lymph nodes or recurrent disease to prevent future locoregional complications [4] .
Unlike the lateral compartment, untreated persistent/ recurrent disease in the central compartment is associated with a significant higher risk of long-term morbidity, including loss or change in voice quality and swallowing because of the proximity of the recurrent laryngeal nerve (RLN) and the aerodigestive tract [6] [7] [8] . Furthermore, it increases the risk of cancer-specific deaths [6] [7] [8] . Therefore, reoperative surgery in the central compartment (RCND) is usually indicated. Although most studies have reported relatively acceptable morbidity, with some reporting rates similar to that for primary CND, morbidity does vary among studies and is subject to publication bias [6, [9] [10] [11] [12] [13] [14] [15] . Furthermore, the efficacy of RCND in disease control remains unclear because not all studies have explicitly analyzed this outcome, particularly in terms of postoperative Tg levels and survival [5] . Thus, we reviewed our experience with RCND, specifically evaluating surgical morbidity and efficacy in regard to disease control.
Patients and methods

Patients
From 1992 to 2011, a total of 1,586 patients underwent surgery for histologically proven PTC. Among them, 50 (3.2 %) patients underwent RCND for persistent/recurrent PTC. We defined RCND as comprehensive bilateral central lymph node dissection in a previously dissected central compartment. Patients who initially underwent thyroidectomy without CND were included. We also included those who developed recurrent tumor in the thyroid remnant and others with previously nonenlarged metastatic central neck lymph nodes or central neck lymph nodes that had not been completely removed during the initial operation. Patients who underwent reexcision of a normal/nontumorous thyroid remnant or excision of lymph nodes only (i.e., ''berrypicking'') in a previously operated on central compartment were excluded. For patients who had undergone one or more RCNDs, for simplicity, only the earliest reoperation was analyzed.
To have a more meaningful comparison of surgical morbidity and disease outcomes of RCND, the 50 patients who had undergone RCND were compared according to a 1.5:1.0 match with patients who underwent a therapeutic primary CND during the same period (i.e., those who underwent CND at the time of thyroidectomy). During this period, there were 159 patients who had undergone a therapeutic primary CND. Those who underwent prophylactic CND were not included. The two groups were matched according to the following criteria: sex, age, tumor size, and initial tumor stage. Matching was performed blinded to the morbidity and disease outcome of each patient. Primary CND consisted of bilateral removal of clinically involved central lymph nodes (cN1) at the time of the initial total thyroidectomy (TT).
Indications and technique for RCND Persistent/recurrent disease was diagnosed using a combination of clinical evidence, USG, fine needle aspiration (FNA), post-radioiodine (RAI) scan, computed tomography (CT), magnetic resonance imaging (MRI), and/or 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG-PET/CT). In general, RCND was preferred for patients with bulky ([8-10 mm) and/or progressive central disease, whereas close observation by regular USG was preferred for those with nonbulky (\5-8 mm) and nonprogressive central disease.
The surgery generally began with an incision along the previous thyroidectomy incision. If required, the incision was extended laterally. A subplatysmal flap was elevated superiorly and inferiorly elevating the neck flaps. The inferior neck flap was usually elevated well below the sternal notch for easier retraction. The upper part of the strap muscles on the side of reoperation was divided to attain better exposure. For all cases, the RLN was identified first and traced along its course before proceeding to CND. In a densely scarred field, the intraoperative nerve stimulator probe was sometimes used for mapping out the course of the RLN [16] . The RLN was gently dissect from the central neck lymph nodes. The rest of the procedure was performed similar to a primary CND, which was described previously [17] .
Treatment protocol
Details of the treatment and follow-up protocols are described elsewhere [18] . 2 months after surgery, a standard ablative RAI dose of 3 giga-Becquerels (GBq) or 80 millicuries (mCi) was given after LT4 withdrawal or with recombinant thyroid-stimulating hormone (rTSH). TSHsuppressive LT4 treatment was commenced immediately afterward. External beam radiotherapy (ERT) to the neck was given to patients with extensive extrathyroidal tumor extension, incomplete resection, and/or extracapsular lymph node metastasis (40 Gy over 3 weeks for adjuvant treatment and 50 Gy over 4 weeks for gross residual disease). All treatment decisions were made at a multidisciplinary meeting.
Complications
Both vocal cords were examined preoperatively and within 1 week of surgery. Any reduced cord movement was recorded as vocal cord palsy. Those with palsy were examined every 6-8 weeks by otolaryngologists during the first 6 months. The presence of palsy lasting [6 months was regarded as permanent. To calculate vocal cord palsy rates, the number of nerves at risk was used as denominator. Calcium±calcitriol supplements were given selectively. For hypoparathyroidism, those taking calcium±calcitriol supplements were slowly weaned off their supplements. By definition, those who discontinued all supplements in the presence of normocalcemia B6 months after surgery were regarded as having temporary hypoparathyroidism, whereas those who continued for [6 months were categorized as having permanent hypoparathyroidism.
Surveillance
All data, including disease status and cause of death, were prospectively collected after 1995. Follow-up visits was scheduled at 3-month intervals during the first 2 years, every 6 months for the subsequent 3 years, and annually thereafter. In addition to a clinical examination, USG of the neck and Tg levels were obained at each follow-up. All Tg levels were measured in the same laboratory using the same immunometric assay (Immulite 2000; Diagnostic Products Corp., Roche, Los Angeles, CA, USA). They were calibrated against the CRM-457 standard. A stimulated Tg (sTg) level \2.0 lg/l was considered undetectable. The normal reference range was\0.5-55.0 lg/l with the sensitivity\0.2 lg/ l. Clinical recurrences were diagnosed by USG, CT/MRI, or FDG-PET scan and confirmed by FNA cytology. Survival data including the cause of death were retrieved from the territory-wide computerized medical system and from death certificates or postmortem examinations.
Statistical analysis
Statistical analysis was performed by the v 2 or Fisher's exact test to compare categoric variables. The MannWhitney U test was used to compare continuous variables between groups. Continuous variables were expressed as medians with ranges. In the RCND group, survival and duration of follow-up were calculated from the time of RCND to the date of the last follow-up or death. In the primary CND group, it was taken from the time of the primary CND. Disease-free survival (DFS) and CSS were calculated using the Kaplan-Meier method. Survival outcomes were compared using the log-rank test. All statistical analyses were performed using SPSS version 18.0 software (SPSS, Chicago, IL, USA). Table 1 shows the baseline characteristics of the 50 patients who underwent RCND. In all, 34 patients underwent their initial operation at our institution, whereas the other 16 had their initial operation performed elsewhere. All patients underwent 3 GBq RAI ablation after the initial operation. Only one (2.0 %) patient underwent ERT following the initial operation. All had imageable one-sided recurrence in the central compartment. Among them, 7 (14.0 %) patients had palpable central neck recurrence. USG and FDG-PET/CT comprised the most common combination for disease staging before surgery. Two (4.0 %) patients had evidence of distant metastases at the time of RCND. Of the 20 patients who underwent RCND only, two also underwent mediastinal clearance via sternotomy for bulky upper mediastinal disease. Of the six patients who underwent tumor remnant excision, four underwent tumor remnant excision and CND. The other two patients underwent tumor remnant excision, CND, and lateral selective neck dissection. Two patients in this tumor remnant excision subgroup also required tumor shaving from the trachea. The common sites for persistent/recurrent disease were adjacent to the RLN (38.0 %), followed by paratracheal (34.0 %) and paraesophageal (14.0 %) sites. Of the 20 (i.e., 12 ? 8) patients who underwent CND at the initial operation and developed subsequent detectable recurrence on one side, 6 (30.0 %) had microscopic or occult positive nodes on the other side. Table 2 shows a comparison of clinicopathologic factors between those who underwent primary CND and RCND. As expected, age, sex, tumor size, and primary tumor stage were comparable between the two groups. In terms of pathologic findings, the median number of central lymph nodes (CLNs) retrieved (7 vs. 7, p = 0.489), positive CLNs examined (3 vs. 4, p = 0.095), and the lymph node ratio (LNR) (52.3 vs. 57.2 %, p = 0.512) were similar in the two groups The incidence of incidental parathyroid gland on the excised specimen was also similar in the two groups (17.3 vs. 18.0 %, p = 0.936). However, the presence of extranodal extension was significantly more frequent in the RCND group than in primary CND group (36.0 vs. 14.7 %, p = 0.010). Also, the median size of the metastatic central lymph node in the RCND group was significantly larger than in the primary CND group (15 vs. 12 mm, p \ 0.001). Table 3 shows a comparison of morbidity and disease outcomes between the primary CND and RCND groups. The temporary hypoparathyroidism rate was comparable for the two groups (8.0 vs. 14.0 %, p = 0.383). After excluding the eight patients who had been taking calcium supplements before surgery in the RCND group, the permanent hypoparathyroidism rate was similar between the two groups (1.3 vs. 0 %, p = 1.000). The numbers of nerves at risk in the primary CND and RCND groups were 150 and 100, respectively. After excluding the six patients with preoperative unilateral vocal cord palsy (due to tumor invasion of the RLN), both temporary and permanent vocal cord palsy rates were similar in the two groups. Apart from hypoparathyroidism and vocal cord palsy, two patients in the RCND group suffered cervical esophageal injury. One of the injuries was recognized intraoperatively and was repaired, but the other was recognized 2 days after surgery and required reoperation. In retrospect, both patients had undergone incomplete primary tumor excision at the initial operation, and both tumors had recurred and partially invaded the esophageal wall. The total morbidity rate was similar for two groups (20.0 vs. 28.0 %, p = 0.210). There were no in-hospital deaths. Within the RCND group, temporary hypoparathyroidism and vocal cord palsy rates were comparable for those who had previously undergone TT and those with previous TT and neck dissection (4/27 vs. 3/23, p = 1.000 and 3/27 vs. 3/23, p = 1.000, respectively).
Results
All patients after secondary CND underwent RAI ablation, and three had additional ERT. The rate of detectable sTg (i.e., sTg C2 ng/ml) was significantly higher in the secondary CND group (p = 0.001). Despite the shorter median duration of follow-up, the number of postoperative recurrences was significantly higher in the secondary group than in the primary group (26.0 vs. 6.7 %, p = 0.008). They also tended to be more likely to undergo subsequent reoperation than did those in the primary CND group (12.0 vs. 2.7 %, p = 0.066). The central compartment recurrences were also significantly more numerous in the secondary group than in the primary group (12.0 vs. 0 %, p = 0.011). Other sites of recurrence were similar for the two groups. Figure 1 shows the DFS survival curves for the primary and secondary groups. 
Discussion
Consistent with previous studies, our data suggested that in well-selected cases the morbidity associated with RCND for persistent/recurrent PTC was comparable to that of primary CND [9, 10] . Table 4 compares the complications, sTg levels, and locoregional recurrencees between our study and others. After excluding patients with preexisting hypoparathyroidism or vocal cord palsy before RCND, the temporary and permanent rates of these complications were similar between the two groups. However, it is worth noting that two (4.0 %) patients in the RCND group suffered iatrogenic injury to the cervical esophagus. Although one injury was recognized and repaired intraoperatively without sequela, the other injury was missed and only recognized 2 days after surgery. That patient later developed an esophagocutaneous fistula requiring a prolonged hospital stay. In retrospect, these two injuries were probably a direct result of the tumor invading part of the esophagus. Therefore, in our opinion, although serious complications such as esophageal injury can result after RCND, the total morbidity associated with RCND appeared relatively acceptable and comparable to that of primary CND (28.0 vs. 20.0 %, p = 0.210). Nevertheless, the decision to apply RCND should not be taken lightly and should be undertaken only after weighing the risks and benefits of surgical reoperation and the risk of disease. The other aspect our study evaluated was disease control after RCND, which was assessed both biochemically and clinically. Using sTg \2 ng/ml as indicating biochemically undetectable disease, the RCND group achieved a significantly lower rate of undetectable postablation sTg than did the primary CND group (12.0 vs. 52.0 %, p \ 0.001) despite the fact that the two groups were matched for sex, age, tumor size, and initial tumor stage. However, this finding was not entirely unexpected because the surgical indications between the two groups were quite different. Approximately half of the RCNDs were performed because of the bulkiness of the disease, and the other half were were undertaken because of disease progression. In contrast, primary CND was usually done when there was clinical evidence of central lymph node metastasis (i.e., cN1) at the time of the initial TT. As a result, the RCND group had more advanced nodal disease, as reflected by the greater incidence of extranodal extension (36.0 vs. 14.7 %, p = 0.010) and the size of metastatic CLNs (17 vs. 12 mm, p \ 0.001), than did the primary CND group. Similarly, the incidence of preoperative unilateral vocal cord palsy in the RCND group was higher than that of the primary CND group (14.0 vs. 0 %).
Apart from the undetectable postablation sTg level, the overall recurrence rate in the RCND group was significantly higher than in the primary CND group (26.0 vs. 6.7 %, p = 0.008). Although the rates might appear high, they were comparable to those in other similar series [6, 8, 10, 15] . Of the 13 clinically detectable recurrences in the RCND group, 8 (61.5 %) occurred either in the central or the central and lateral compartments. In contrast, of the five clinical recurrences in the primary CND group, only one (20.0 %) occurred in the central compartment. This implied that despite performing a fairly comprehensive RCND, disease control in the central compartment was moderate. It is also worth noting that of the 13 clinical recurrences 5 (38.5 %) (excluding the two patients with distant The rate of VCP was calculated based on number of nerves at risk and those with the involved RLN requiring intentional resection were excluded. Also, the rate of hypoCa was calculated based on patients with normal preoperative parathyroid function VCP vocal cord palsy, hypoCa hypocalcemia, sTg, rate of detectable stimulated thyroglobulin, LRR locoregional recurrence a Basal thyroglobulin metastases before reoperation) developed distant disease. In fact, the 10-year DFS and CSS were significantly worse in the RCND group than in the primary group (respectively, 35.6 vs. 91.8 %, p = 0.001 and 82.0 vs. 98.5 %, p = 0.001). These findings underlined the importance of administering adjuvant treatment after RCND as the tumor not only tended to recur locally but also at distant sites. Our results should be interpreted cautiously because the surgical indications and selection process for primary and RCND were different (i.e., selection bias). For example, primary CND was done simply as part of the initial operation, whereas the reason for RCND was to ''prevent'' future morbidity because of the bulkiness or progression of the central disease. Also, selection bias could not be completely ruled out because this was a retrospective study. In addition, the RCND group was rather heterogeneous in terms of patients undergoing different extents of the initial operation prior to reoperation and the different extents of persistent/recurrent disease. Some patients underwent only TT without CND, whereas others had TT with CND as the initial procedure. Ideally, these patients should have been analyzed separately but because the number of patients was small we did not further perform subgroup analyses. Nevertheless, based on our data the temporary hypoparathyroidism and vocal cord palsy rates appeared similar between the two subgroups.
Because RCND remains the only effective treatment for bulky and progressive central disease to prevent complications, the indication for RCND should remain unchanged despite the relatively poor long-term disease control. It remains unclear if performing RCND at an earlier stage (i.e., before the disease becomes [8-10 mm or progressive) would significantly reduce the morbidity and improve long-term disease outcomes.
Conclusions
Overall, in well-selected cases, RCND for persistent/recurrent PTC can be performed with morbidity comparable to associated with primary CND. Nevertheless, it may be associated with some serious complications depending on the findings at the initial operation. In terms of disease control after RCND, only approximately one-tenth of the patients had an undetectable postablation sTg level at 6 months after surgery. One-third were clinically disease-free after 10 years.
